Market Place
Sourcing Support
Volastra taps CSO as it looks to expand research horizons
16 Oct 2024 //
FIERCE BIOTECH
Volastra Appoints Samuel Bakhoum As Chief Scientific Officer
16 Oct 2024 //
BUSINESSWIRE
Volastra`s Ovarian Cancer Drug Gets FDA Fast Track Status
02 Oct 2024 //
BUSINESSWIRE
Volastra Doses First SovilnesibPhase 1b Patient
16 Apr 2024 //
BUSINESSWIRE
Volastra Announces New and Expanded Partnerships with AI and Precision-Medicine
26 Mar 2024 //
BUSINESSWIRE
Function Announces Innovative Precision Medicine Partnership with Volastra
26 Mar 2024 //
BUSINESSWIRE
Volastra Therapeutics Appoints David Nicholson, Ph.D., to Board of Directors
06 Nov 2023 //
BUSINESSWIRE
Volastra Announces First Patient Dosed in Phase I/II Clinical Trial of VLS-1488
30 Oct 2023 //
BUSINESSWIRE
Amgen out-licenses KIF18A inhibitor sovilnesib to Volastra
08 Mar 2023 //
BUSINESSWIRE
Volastra buys clinical cancer med from Amgen, tacks on $60M
07 Mar 2023 //
FIERCE BIOTECH
OpenBench Teams Up with Volastra to Discover Early Research Hits
18 Oct 2022 //
PRNEWSWIRE
Volastra Therapeutics to Present Preclinical Data from KIF18A Inhibitor Program
09 Sep 2022 //
BUSINESSWIRE
Copyright © 2025 LePro PharmaCompass OPC Private Limited, All rights reserved.